eFFECTOR Therapeutics, Inc. (EFTR): Price and Financial Metrics
GET POWR RATINGS... FREE!
EFTR Stock Summary
- EFTR has a market capitalization of $15,391,642 -- more than approximately just 6.48% of US stocks.
- With a one year PEG ratio of 0.31, EFFECTOR THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 3.97% of US stocks.
- Revenue growth over the past 12 months for EFFECTOR THERAPEUTICS INC comes in at 148.46%, a number that bests 95.04% of the US stocks we're tracking.
- Stocks that are quantitatively similar to EFTR, based on their financial statements, market capitalization, and price volatility, are UBX, BPMC, VLN, FUSN, and RXRX.
- To check out EFFECTOR THERAPEUTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001828522.
EFTR Valuation Summary
- In comparison to the median Healthcare stock, EFTR's price/earnings ratio is 103.1% lower, now standing at -0.7.
- Over the past 27 months, EFTR's EV/EBIT ratio has gone up 4.9.
Below are key valuation metrics over time for EFTR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EFTR | 2023-03-17 | 4.4 | 4.0 | -0.7 | -1.3 |
| EFTR | 2023-03-16 | 4.7 | 4.3 | -0.7 | -1.4 |
| EFTR | 2023-03-15 | 4.8 | 4.4 | -0.8 | -1.4 |
| EFTR | 2023-03-14 | 4.8 | 4.4 | -0.8 | -1.4 |
| EFTR | 2023-03-13 | 4.8 | 4.4 | -0.8 | -1.4 |
| EFTR | 2023-03-10 | 5.3 | 4.8 | -0.8 | -1.5 |
EFTR Stock Price Chart Interactive Chart >
EFTR Price/Volume Stats
| Current price | $0.36 | 52-week high | $4.98 |
| Prev. close | $0.36 | 52-week low | $0.35 |
| Day low | $0.35 | Volume | 69,500 |
| Day high | $0.38 | Avg. volume | 397,136 |
| 50-day MA | $0.50 | Dividend yield | N/A |
| 200-day MA | $0.68 | Market Cap | 15.20M |
eFFECTOR Therapeutics, Inc. (EFTR) Company Bio
eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. The company was incorporated in 2012 and is based in San Diego, California.
Latest EFTR News From Around the Web
Below are the latest news stories about EFFECTOR THERAPEUTICS INC that investors may wish to consider to help them evaluate EFTR as an investment opportunity.
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateZotatifin continued to demonstrate favorable activity and tolerability, including two previously reported confirmed partial responses (PRs) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A) Enrollment in expanded ECBF+A cohort completed and data is anticipated in first half of 2023 Topline data for Phase 2b KICKSTART trial in NSCLC anticipated in second half of 2023 Cash runway anticipated into first quarter of 2024 SOLANA BEACH and REDWOOD CITY |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Monday! |
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVIDResults presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced top-line results from its Phase 1b clinical trial of zotatifin for the treatment of COVID demonstrating favorable safety results as well as positive trends in s |
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor ConferenceSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY. Steve Worland, Ph.D., president and chief executive officer of eFFECTOR, will provide an overview of the Company |
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate UpdateZotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated subjects who received zotatifin, fulvestrant and abemaciclib (ECBF+A), with good tolerability eFFECTOR to focus on front-line PD-L1 ≥ 50% cohort of KICKSTART trial with tomivosertib in non-small cell lung cancer Management to present results and provide full pipeline update in investor call on January 5, 2023 at 4:30 p.m. ET SOLANA BEACH, Calif. and REDWOOD CITY, |
EFTR Price Returns
| 1-mo | -28.01% |
| 3-mo | -14.27% |
| 6-mo | -36.05% |
| 1-year | -92.26% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -15.81% |
| 2022 | -94.84% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...